About AuriSignum
AuriSignum is a Healthcare company based in Thane (India) founded in 2016. It offers characterization services for biopharmaceuticals including proteins and antibodies. It operates on a B2B model. The company has 193 employees. Its Indian entity Biogenomics Limited reported revenue of ₹13.42 Cr. AuriSignum offers products and services including Product Characterization Assays, Bioassay Development, and Pharmacokinetics Services. Its focus areas include Biotech Services, Analytical Development, Assay Testing and Biopharmaceuticals.
Company details
Auri Signum delivers comprehensive biopharmaceutical characterization services, covering assays for peptides, proteins, and monoclonal antibodies. They assist in drug discovery, process development, and product release, using advanced facilities and regulatory expertise. Based in Thane, India, they serve biotech companies by speeding up timelines and reducing costs through end-to-end solutions like purity and activity assays.
- Headquarters Thane, India
- Employees 193
- SectorsHealthcare
- Email••••••••
- Website aurisignum.com
- Legal Name Biogenomics Limited
- Date of Incorporation 24 Apr, 2002
- Jurisdiction Puducherry, India
- Annual Revenue₹13.42 Cr
FY 2024
- Net Loss-₹24.00 Cr
FY 2024 · -179% margin
- EBITDA-₹26.37 Cr
FY 2024 · -197% margin
- Employee Count193
Associated legal entities of AuriSignum
AuriSignum operates through Biogenomics Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Biogenomics Limited CIN U24234PY2002PLC009158 | Active | 24 Apr 2002 | Puducherry, Puducherry | ₹13.4 Cr | 193 | 11 | View details |
Products & Services of AuriSignum
AuriSignum offers a comprehensive portfolio of products and services, including Product Characterization Assays, Bioassay Development, and Pharmacokinetics Services.
Services for analyzing biopharmaceutical identity and purity.
Testing for biological activity in pharmaceuticals.
Analysis for drug efficacy and immunogenicity studies.
Board of directors of Biogenomics Limited (AuriSignum)
Biogenomics Limited is the primary company behind AuriSignum. The board of Biogenomics Limited currently have 9 directors; the longest-serving is Archana Rajesh Krishnan, appointed in 2006. 24 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Archana Rajesh Krishnan DIN 00208511 | Whole-time director | 03 Feb 2006 | 20 yrs 9 mo | Biogenomics Limited |
| Namit Rustagi DIN 09493933 | Director | 28 Mar 2022 | 4 yrs 7 mo | Biogenomics Limited |
| Ammar Abdullah Hamad Al Ali DIN 09538218 | Director | 28 Mar 2022 | 4 yrs 7 mo | Biogenomics Limited |
| Ali Abdullah Ali Al Aamri DIN 09608439 | Nominee Director | 31 May 2022 | 4 yrs 5 mo | Biogenomics Limited |
| Mohammed Hamdan Saif Al Rubaie DIN 09615093 | Nominee Director | 31 May 2022 | 4 yrs 5 mo | Biogenomics Limited |
| Pushkar Jauhari DIN 06391650 | Nominee Director | 19 Jun 2022 | 4 yrs 4 mo | Biogenomics Limited |
| Rajesh Shashikant Dalal DIN 03504969 | Director | 08 Dec 2023 | 2 yrs 11 mo | Biogenomics Limited |
| Imran Jamiluddin Shaikh DIN 10723912 | Nominee Director | 20 Aug 2024 | 2 yrs 2 mo | Biogenomics Limited |
| Rajiv Malik DIN 00334785 | Additional Director | 01 Jul 2025 | 1 yr 4 mo | Biogenomics Limited |
Financials of AuriSignum
Figures of Biogenomics Limited, the primary company behind AuriSignum, for FY 2024. Revenue was ₹13.42 Cr. Net loss was -₹24.00 Cr (-179% margin). EBITDA was -₹26.37 Cr (-197% margin).
- ₹13.42 CrRevenue · FY 2024
- -₹24.00 CrNet loss · -179% margin
- -₹26.37 CrEBITDA · -197% margin
- ₹384 CrPaid-up capital
- 193Employees (provident fund records)
Balance sheet, profit and loss, cash flow and ratios of Biogenomics Limited are on its company page.
Detailed financial statements for AuriSignum
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aurisignum
Complete news archive for AuriSignum
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AuriSignum
AuriSignum was founded in 2016.
AuriSignum is headquartered in Thane, India. It is registered at Thane, Maharashtra, India.
AuriSignum has 193 employees.
The primary company behind AuriSignum, Biogenomics Limited, reported revenue of ₹13.42 Cr for FY 2024.
Auri Signum delivers comprehensive biopharmaceutical characterization services, covering assays for peptides, proteins, and monoclonal antibodies. They assist in drug discovery, process development, and product release, using advanced facilities and regulatory expertise. Based in Thane, India, they serve biotech companies by speeding up timelines and reducing costs through end-to-end solutions like purity and activity assays.
AuriSignum offers Product Characterization Assays, Bioassay Development, and Pharmacokinetics Services.
AuriSignum operates through Biogenomics Limited.
The legal entities of AuriSignum currently have 11 directors, including Pushkar Jauhari, Rajesh Shashikant Dalal, Rajiv Malik and others.